18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

Abstract Background Positron emission tomography (PET) is poised to become a useful imaging modality in staging and evaluating therapeutic responses in patients with metastatic pancreatic cancer (mPC). This analysis from a phase 1/2 study examined the utility of early PET imaging in patients with mP...

Full description

Bibliographic Details
Main Authors: Ronald L. Korn, Daniel D. Von Hoff, Mitesh J. Borad, Markus F. Renschler, Desmond McGovern, R. Curtis Bay, Ramesh K. Ramanathan
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Cancer Imaging
Subjects:
Pancreatic cancer
nab-Paclitaxel
Gemcitabine
Phase 1/2 clinical trial
Positron emission tomography
Online Access:http://link.springer.com/article/10.1186/s40644-017-0125-5

Internet

http://link.springer.com/article/10.1186/s40644-017-0125-5

Similar Items